What is the price target for TNXP stock?
8 analysts have analysed TNXP and the average price target is 67.66 USD. This implies a price increase of 318.69% is expected in the next year compared to the current price of 16.16.
TONIX PHARMACEUTICALS HOLDIN (TNXP) Forecast, Price Target & Analyst Ratings
NASDAQ:TNXP • US8902608392
Current stock price
16.16 USD
+0.39 (+2.47%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TONIX PHARMACEUTICALS HOLDIN (TNXP).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$2.63
- Revenue Estimate
- 13.209M
Price Target Details & History
Consensus Price Target and Range
Mean target
$67.66
Upside
+ 318.69%
From current price of $16.16 to mean target of $67.66, Based on 8 analyst forecasts
Low
$64.64
Median
$66.30
High
$73.50
Price Target Revisions
1 Month
0.00%
3 Months
-1.97%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for TNXP. The average price target is 67.66 USD. This implies a price increase of 318.69% is expected in the next year compared to the current price of 16.16.
The average price target has been revised downward by 1.97% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
TNXP was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TNXP.
In the previous month the buy percentage consensus was at a similar level.
TNXP was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-03-20 | Noble Capital Markets | Reiterate | Outperform -> Outperform |
| 2024-07-22 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2024-02-28 | Dawson James | Initiate | Buy |
| 2023-08-01 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2023-06-02 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2023-01-12 | Alliance Global Partners | Reiterate | Buy |
| 2022-04-18 | Noble Capital Markets | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$2.63
- Revenue Estimate
- 13.209M
- Revenue Q2Q
- 443.80%
- EPS Q2Q
- 7.52%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-17.97%
EPS (1 Month)
0.00%
EPS (3 Months)
23.59%
Next Earnings Summary
TNXP is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -2.63 USD and the consensus revenue estimate is 13.21M USD.
The next earnings revenue estimate has been revised downward by 17.97% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.768M | 10.094M 29.94% | 13.107M 29.85% | 87.312M 566.15% | 118.78M 36.04% | 125.51M 5.67% | |
| EBITDA YoY % growth | -114.089M -2.93% | -74.323M 34.86% | -123.778M -66.54% | N/A | N/A | N/A | |
| EBIT YoY % growth | -118.38M -5.61% | -77.744M 34.33% | -125.703M -61.69% | -107.699M 14.32% | -66.917M 37.87% | -105.066M -57.01% | |
| Operating Margin | -1,523.94% | -770.20% | -959.05% | -123.35% | -56.34% | -83.71% | |
| EPS YoY % growth | -27,584.00 66.11% | -2,536.77 90.80% | -14.27 99.44% | -7.95 44.27% | -3.15 60.37% | -2.14 32.04% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -2.63 7.52% | -2.30 40.54% | -1.92 46.58% | -1.31 67.20% |
| Revenue Q2Q % growth | 13.209M 443.80% | 37.842M 1,793.99% | 58.344M 1,673.37% | 88.944M 1,550.17% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
22.76%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
126.50%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
TONIX PHARMACEUTICALS HOLDIN / TNXP Forecast FAQ
When does TONIX PHARMACEUTICALS HOLDIN (TNXP) report earnings?
TONIX PHARMACEUTICALS HOLDIN (TNXP) will report earnings on 2026-05-11.
What are the consensus estimates for TONIX PHARMACEUTICALS HOLDIN (TNXP) next earnings?
The consensus EPS estimate for the next earnings of TONIX PHARMACEUTICALS HOLDIN (TNXP) is -2.63 USD and the consensus revenue estimate is 13.21M USD.
How many analysts have analysed TONIX PHARMACEUTICALS HOLDIN (TNXP)?
The number of analysts covering TONIX PHARMACEUTICALS HOLDIN (TNXP) is 8.